PRG Science & Technology Co., Ltd. | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Nutritional and Metabolic Diseases, Werner syndrome, hereditary disease, metabolic disease	Recruiting	Phase 2	2026-10-05		NCT05847179
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis	Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder	Recruiting	Phase 1	2026-03-05		NCT07221240
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ear Diseases, NF2-related schwannomatosis, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Otorhinolaryngologic Neoplasms, acoustic neuroma, cranial nerve neoplasm, cranial nerve neuropathy, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neuroendocrine neoplasm, neurofibroma, neurofibromatosis, neuroma, otorhinolaryngologic disease, primitive neuroectodermal tumor, retrocochlear disease, schwannoma, vestibulocochlear nerve disorder	Not yet recruiting	Phase 1 / Phase 2	2026-01-23		NCT07131722